Eyenovia Reports First Quarter 2021 Financial Results
12 mai 2021 16h05 HE
|
Eyenovia, Inc.
MydCombi PDUFA date confirmed for October 28, 2021 Completed patient enrollment in Phase 3 VISION-1 study evaluating MicroLine for the treatment of presbyopia; top-line data on track for Q2 Secures...
Eyenovia Announces New $25 Million Credit Facility with Silicon Valley Bank
10 mai 2021 08h30 HE
|
Eyenovia, Inc.
NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...
Eyenovia to Report First Quarter 2021 Results on Wednesday, May 12
05 mai 2021 08h00 HE
|
Eyenovia, Inc.
NEW YORK, May 05, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array...
Eyenovia Reports Fourth Quarter and Full Year 2020 Financial Results
25 mars 2021 16h05 HE
|
Eyenovia, Inc.
Announces MydCombi expected PDUFA date of October 28, 2021 Completes patient enrollment in Phase 3 VISION-1 study evaluating MicroLine for the treatment of presbyopia; topline data on track for Q2 ...
Eyenovia to Report Fourth Quarter and Full Year 2020 Results on Thursday, March 25
18 mars 2021 08h00 HE
|
Eyenovia, Inc.
NEW YORK, March 18, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose...
Eyenovia to Participate in the 33rd Annual Roth Conference
10 mars 2021 08h00 HE
|
Eyenovia, Inc.
NEW YORK, March 10, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of pipeline of advanced therapeutics based on its proprietary...
Eyenovia to Host Key Opinion Leader Webinar on Presbyopia
16 févr. 2021 08h00 HE
|
Eyenovia, Inc.
NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...
Eyenovia to Participate in Presbyopia Panel Discussion at the LifeSci Partners 10th Annual Corporate Access Event
06 janv. 2021 08h00 HE
|
Eyenovia, Inc.
NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...
Eyenovia Reports Third Quarter 2020 Financial Results
10 nov. 2020 16h06 HE
|
Eyenovia, Inc.
NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...
Eyenovia to Report Third Quarter 2020 Results on Tuesday, November 10
05 nov. 2020 08h00 HE
|
Eyenovia, Inc.
NEW YORK, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...